# Allogene Therapeutics Announces Planned CEO Succession
Canonical URL: https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession
Ticker: ALLO
Company: Allogene Therapeutics
Source: Allogene Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.allogene.com
## Summary

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief

## Article Body
David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief
## Recent Company News
- 2026-06-25 13:46 EST — [Allogene Therapeutics Announces Planned CEO Succession](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Announces Participation in Upcoming Investor Conferences](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-participation-in-upcoming-investor-conferences) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-first-quarter-2026-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-update) — Source: Allogene Therapeutics
- 2026-06-25 13:46 EST — [Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-announce-interim-futility-analysis-data-from-its-pivotal-phase-2-alpha3-trial-with-cemacabtagene-ansegedleucel-cema-cel-in-first-line-consolidation-lbcl-on-monday-april-13-2026) — Source: Allogene Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)